Diagnostic pathways to wild‐type transthyretin amyloid cardiomyopathy: a multicentre network study

Epidemiology of wild‐type transthyretin cardiac amyloidosis (ATTRwt‐CA) remains poorly defined. A better characterization of pathways leading to ATTRwt‐CA diagnosis is of key importance, and potentially informative of disease course and prognosis. The aim of this study was to describe the characteristics of contemporary pathways leading to ATTRwt‐CA diagnosis, and their potential association with survival.

[1]  L. Lund,et al.  Temporal Trends of Heart Failure Hospitalizations in Cardiology Versus Noncardiology Wards According to Ejection Fraction: 16-Year Data From the SwedeHF Registry , 2022, Circulation. Heart failure.

[2]  M. Benson,et al.  Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis , 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[3]  J. Smith,et al.  Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries , 2022, ESC heart failure.

[4]  M. Emdin,et al.  Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies , 2022, European journal of heart failure.

[5]  G. Parati,et al.  Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey , 2022, European journal of heart failure.

[6]  F. Rutten,et al.  Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience , 2022, European heart journal open.

[7]  Sanjiv J. Shah,et al.  Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey , 2021, JACC. CardioOncology.

[8]  P. de Paepe,et al.  Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications , 2021, Acta cardiologica.

[9]  C. Autore,et al.  Yield of bone scintigraphy screening for transthyretin‐related cardiac amyloidosis in different conditions: Methodological issues and clinical implications , 2021, European journal of clinical investigation.

[10]  C. Di Mario,et al.  Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. , 2021, Mayo Clinic proceedings.

[11]  N. Fine,et al.  Prevalence and Prognostic Significance of Frailty Among Patients With Transthyretin Amyloidosis Cardiomyopathy. , 2021, Circulation. Heart failure.

[12]  A. Masri,et al.  Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review , 2021, Cardiology and Therapy.

[13]  C. Di Mario,et al.  Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany. , 2021, International journal of cardiology.

[14]  U. Eriksson,et al.  Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases , 2021, European journal of heart failure.

[15]  A. Masri,et al.  Recipe for Success in Transthyretin Cardiomyopathy: Monoclonal Protein Rule Out, SPECT Imaging, and Genetic Testing. , 2020, JACC. Cardiovascular imaging.

[16]  E. Ashley,et al.  Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy , 2020, Circulation. Heart failure.

[17]  P. Cintas,et al.  Gateway and journey of patients with cardiac amyloidosis , 2020, ESC heart failure.

[18]  I. Porto,et al.  Characteristics of current heart failure patients admitted to internal medicine vs. cardiology hospital units: the VASCO study , 2020, Internal and Emergency Medicine.

[19]  Sanjiv J. Shah,et al.  Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy , 2020, Circulation.

[20]  G. Parati,et al.  Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. , 2020, International journal of cardiology.

[21]  G. Felker,et al.  Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy , 2019, JACC. CardioOncology.

[22]  C. Rapezzi,et al.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. , 2019, Circulation. Heart failure.

[23]  A. Petrie,et al.  Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. , 2019, Circulation.

[24]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[25]  F. Dominici,et al.  Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. , 2019, Circulation. Heart failure.

[26]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[27]  R. Falk,et al.  ‘A new staging system for cardiac transthyretin amyloidosis’: is it already on the verge of obsolescence? , 2018, European heart journal.

[28]  C. Rapezzi,et al.  Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.

[29]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.